Drag the processes that are involved in the carbon cycle into the box.

Wei W, Zhao H, Wang A, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic

marshall27 [118]

A group of Chinese women with PCOS who were receiving treatment saw several metabolic and hormonal imbalances improve after taking BBR. The primary consequences may be connected to the modifications in body composition in obesity and dyslipidemia. For the evaluation of the possible beneficial metabolic effects of BBR in women with PCOS, additional controlled trials are required.

PCOS:

Objective: Insulin resistance is a common metabolic and reproductive condition called polycystic ovarian syndrome (PCOS) (IR). A quinoline derivative alkaloid known as berberine (BBR) has been utilized as an insulin sensitizer and is isolated from Chinese medicinal herbs. There may be a therapeutic benefit for PCOS from BBR. The purpose of this study was to compare the effects of BBR and metformin (MET) on the metabolic characteristics of PCOS-affected women.
Design and methods: Ninety nine PCOS and IR patients were randomly assigned to one of three therapy groups: BBR+ compound cyproterone acetate (CPA; $n=31$ ), MET $+$ CPA $(n=30)$ , and placebo $+$ CPA $(n=28)$ for $3$ months. Before and after the treatment period, metabolic and hormonal measures as well as the clinical characteristics of the women were evaluated.
Results: Reduced waist circumference, waist-to-hip ratio (WHR;P< $0.01$ ), total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDLC; P< $0.05$ ), as well as increased levels of high-density lipoprotein cholesterol (HDLC) and sex hormone-binding globulin (SHBG; P< $0.05$ ) were all observed following treatment with BBR as compared to MET. Similarly, BBR treatment decreased WHR, fasting plasma glucose, fasting insulin, homeostasis model evaluation for IR, area under the insulin curve, TC, LDLC, and TG (P< $0.05$ ), while increasing HDLC and SHBG (P< $0.01$ ) as compared to placebo.